Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KPL-716 (Vixarelimab) in chronic pruritus diseases
NCT03858634Phase 2Completed
- Sponsor
- Genentech
- Start
- May 2019
- Primary completion
- Apr 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of vixarelimab in chronic idiopathic urticaria (CIU), chronic idiopathic pruritus, lichen planus (LP), lichen simplex chronicus (LSC), plaque psoriasis, sponsored by Genentech. Started May 2019; status: completed.
02
Drugs
vixarelimab
03
Conditions
chronic idiopathic urticaria (CIU)chronic idiopathic prurituslichen planus (LP)lichen simplex chronicus (LSC)plaque psoriasis
Beyond the preview
Go deeper on NCT03858634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03858634.